Tirofiban after bridging therapy for acute stroke due to large artery blockage
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether adding a medicine called tirofiban (which helps prevent blood clots) after standard stroke treatment can improve recovery in people who had a stroke due to a blocked large artery in the brain. It is for people who already received a clot-busting drug and a mechanical clot removal procedure, and who have not fully recovered.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a recent stroke (within 24 hours) that was treated with a clot-busting drug followed by a mechanical clot removal procedure (called bridging therapy).
- The stroke must be caused by a blockage in a large artery in your neck or brain, likely due to hardening of the arteries (atherosclerosis), not by a blood clot that traveled from the heart.
- You must not have a known history of atrial fibrillation (a type of irregular heartbeat).
- After the clot removal procedure, your blood flow must have been successfully restored, but you may still have some narrowing in the artery.
- You must not have any serious bleeding conditions, severe kidney or liver disease, recent heart problems, or active cancer that would limit your life expectancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a second medicine (tirofiban) to standard clot-busting treatment can help people who are not improving after the first hour. It is for people with a moderate to severe stroke who are not candidates for a clot-removal procedure.
This trial tests adding the anti-clotting drug tirofiban to standard clot removal for people who have a stroke due to a narrowed artery in the brain. The goal is to see if this combination improves outcomes without raising bleeding risk.
This trial tests whether giving a medication called tirofiban directly into the artery (intra-arterially) after a successful clot removal can improve recovery after a stroke. Tirofiban helps prevent new clots from forming, which may reduce the chance of another stroke.
This trial tests a medication called tirofiban given intravenously after standard thrombolysis to see if it improves recovery in people with acute ischemic stroke. It is for those whose symptoms have not improved or are getting worse after initial treatment.
This trial tests whether giving tirofiban (a blood thinner) shortly after the standard clot-busting drug tenecteplase can improve recovery from a moderate stroke. It is for people who have had a stroke within the last few hours and do not have certain risk factors like irregular heart rhythm or recent bleeding.
This trial tests whether starting tirofiban soon after tenecteplase can improve outcomes for people whose stroke symptoms temporarily get worse after treatment. It aims to see if the added medicine can reduce harmful clot-related changes after initial thrombolysis.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.